XML 35 R2.htm IDEA: XBRL DOCUMENT
v3.25.2

S-K 1602, SPAC Registered Offerings | Sep. 05, 2025
--- | ---
SPAC Offering Prospectus Summary [Line Items] |
SPAC Offering Forepart, Security Holders Have the Opportunity to Redeem Securities [Flag] | true
SPAC Offering Forepart, Security Holder Redemptions Subject to Limitations [Flag] | true
SPAC, Securities Offered, Redemption Rights [Text Block] | We will provide our public shareholders with the opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of our initial business combination either (i) in connection with a general meeting called to approve the business combination or (ii) without a shareholder vote by means of a tender offer. If we seek shareholder approval, we will complete our initial business combination only if we receive an ordinary resolution under Cayman Islands law and our amended and restated memorandum and articles of association, which requires the affirmative vote of a simple majority of the votes cast by such shareholders as, being entitled to do so, vote in person or, where proxies are allowed, by proxy at the applicable general meeting of the company, voting together as a single class. The decision as to whether we will seek shareholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require us to seek shareholder approval under applicable law or stock exchange listing requirement.
SPAC Offering Forepart, De-SPAC Consummation Timeframe Description [Text Block] | We have until the date that is 24 months from the closing of this offering or until such earlier liquidation date as our board of directors may approve, to consummate our initial business combination. If we anticipate that we may be unable to consummate our initial business combination within such 24-month period, we may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination.
SPAC Offering Forepart, De-SPAC Consummation Timeframe | 24 months
De-SPAC Consummation Timeframe, How Extended [Text Block] | we may seek shareholder approval to amend our amended and restated memorandum and articles of association to extend the date by which we must consummate our initial business combination.
De-SPAC Consummation Timeframe Extension, Security Holders Voting or Redemption Rights [Flag] | true
SPAC Offering Forepart, De-SPAC Consummation Timeframe May be Extended [Flag] | true
De-SPAC Consummation Timeframe, Plans if it Fails [Text Block] | If we are unable to complete our initial business combination within 24 months from the closing of this offering and do not hold a shareholder vote to amend our amended and restated memorandum and articles of association to extend the amount of time we will have to consummate an initial business combination, or by such earlier liquidation date as our board of directors may approve, from the closing of this offering, we will redeem 100% of the public shares at a per share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned thereon (less taxes payable and up to $100,000 of interest income to pay dissolution expenses), divided by the number of then issued and outstanding public shares, subject to applicable law as further described herein. We expect the pro rata redemption price to be approximately $10.00 per public share (regardless of whether or not the underwriters exercise their over-allotment option), without taking into account any interest or other income earned on such funds. However, we cannot assure you that we will in fact be able to distribute such amounts as a result of claims of creditors
SPAC Will Solicit Shareholder Approval for De-SPAC Transaction [Flag] | true
De-SPAC Consummation Timeframe, Limitations on Extensions [Text Block] | There is no limit on the number of extensions that we may seek; however, we do not expect to extend the time period to consummate our initial business combination beyond 36 months from the closing of this offering.
De-SPAC Consummation Timeframe, Duration | 36 months
De-SPAC Consummation Timeframe, Extension Failure, Consequences to Sponsor [Text Block] | unable to extend the time period to consummate our initial business combination or fail to obtain shareholder approval to extend the completion window, our sponsor’s investment in our founder shares and our private placement warrants will be worthless.
SPAC, Trust or Escrow Account, Material Terms [Text Block] | Nasdaq rules provide that at least 90% of the gross proceeds from this offering and the sale of the private placement warrants be deposited in a trust account. Of the net proceeds we will receive from this offering and the sale of the private placement warrants described in this prospectus, $250,000,000, or $287,500,000 if the underwriters’ over-allotment option is exercised in full ($10.00 per unit in either case), will be deposited into a segregated trust account located in the United States at JP Morgan Chase Bank, N.A. with Continental Stock Transfer & Trust Company acting as trustee, and initially be invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations; the holding of these assets in this form is intended to be temporary and for the sole purpose of facilitating the intended business combination. To mitigate the risk that we might be deemed to be an investment company for purposes of the Investment Company Act, which risk increases the longer that we hold investments in the trust account, we may, at any time (based on our management team’s ongoing assessment of all factors related to our potential status under the Investment Company Act), instruct the trustee to liquidate the investments held in the trust account and instead to hold the funds in the trust account in cash or in an interest bearing demand deposit account at a bank. The proceeds to be placed in the trust account include $10,000,000 (or up to $12,250,000 if the underwriters’ over-allotment option is exercised in full) in deferred underwriting commissions. business combination with respect to our warrants. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and any public shares they may acquire during or after this offering in connection with the completion of our initial business combination.
SPAC, Trust or Escrow Account, Gross Offering Proceeds Placed, Percent | 90.00%
SPAC Additional Financing Plans, Impact on Security Holders [Text Block] | Moreover, depending on, among other factors, the valuation of our business combination target company, we may need to obtain additional financing to complete our initial business combination, either because the transaction requires more cash than is available from the proceeds held in our trust account or because we become obligated to redeem a significant number of our public shares upon completion of the business combination, in which case we may issue additional securities or incur debt in connection with such business combination. If we raise additional funds through equity or convertible debt issuances, our public shareholders may suffer significant dilution and those securities could have rights that rank senior to our public shares. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to our equity securities and could contain covenants that restrict our operations. We may also obtain financing prior to the closing of our initial business combination to fund our working capital needs and transaction costs in connection with our search for and completion of our initial business combination. There is no limitation on our ability to raise funds through the issuance of equity or equity-linked securities or through loans, advances or other indebtedness in connection with our initial business combination, including pursuant to forward purchase agreements or backstop agreements we may enter into following consummation of this offering. If we are unable to complete our initial business combination because we do not have sufficient funds available to us, we will be forced to liquidate the trust account. In addition, following our initial business combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.
SPAC, Actual or Potential Material Conflict of Interest, Prospectus Summary [Text Block] | Conflicts of Interest Under Cayman Islands law, directors and officers owe the following fiduciary duties: • duty to act in good faith in what the director or officer believes to be in the best interests of the company as a whole; • duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose; • duty to not improperly fetter the exercise of future discretion; • duty to exercise authority for the purpose for which it is conferred and a duty to exercise powers fairly as between different sections of shareholders; • duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and • duty to exercise independent judgment. In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge, skill and experience of that director. As set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position at the expense of the company. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders provided that there is full disclosure by the directors. This can be done by way of permission granted in the memorandum and articles of association or alternatively by shareholder approval at general meetings. Each of our officers and directors presently has, and any of them in the future may have additional, fiduciary, contractual or other obligations or duties to one or more other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such entities. Accordingly, if any of our officers or directors becomes aware of a business combination opportunity which is suitable for an entity to which he or she has then current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such other entity (unless presented to them in their capacity as an officer or director of our company) subject to their fiduciary duties under Cayman Islands and any other applicable law. Our amended and restated memorandum and articles of association provide that, to the fullest extent permitted by law: (i) no individual serving as a director or an officer, among other persons, shall have any duty, except and to the extent expressly assumed by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us, and (ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter which (a) may be a corporate opportunity for any director or officer, on the one hand, and us, on the other or (b) the presentation of which would breach an existing legal obligation of a director or officer to any other entity. As a result, the fiduciary duties or contractual obligations of our officers or directors could materially affect our ability to complete our initial business combination. Below is a table summarizing the entities to which our executive officers and directors currently have fiduciary duties, contractual obligations or other material management relationships:
Individual |  | Entity |  | Entity’s Business |  | Affiliation
Thomas Lee(1) |  | Fundstrat Global Advisors |  | Research Advisory |  | Managing Partner and Officer
Chi Tsang(2) |  | M1720 |  | Venture Capital |  | Managing Partner
|  | Kin Euphorics |  | Beverages |  | Officer
Eric Semler(3) |  | TCS Capital Management |  | Family Office |  | Principal
|  | Semler Scientific, Inc. |  | Medical Device and Software |  |
|  | Fundstrat Global Advisors |  | Research Advisory |  | Director
|  | Trailblazer Acquisition Corp. |  | Blank Check |  | Officer and Director
Seth Ginns(4) |  | CoinFund |  | Investments |  | Managing Partner
Sam Englebardt |  | Galaxy |  | Digital Infrastructure |  | Partner
____________ (1) Such person may also be an officer or a director of portfolio companies of Fundstrat Global Advisors and its affiliates, and may be obligated to show acquisitions to such companies before we may pursue such acquisitions. (2) Such person may also be an officer or a director of portfolio companies of M1720 and its affiliates, and may be obligated to show acquisitions to such companies before we may pursue such acquisitions. (3) Such person may also be an officer or a director of portfolio companies of TCS Capital Management and Fundstrat Global Advisors and their affiliates, and may be obligated to show acquisitions to such companies before we may pursue such acquisitions. (4) Such person may also be an officer or a director of portfolio companies and entities of CoinFund and its affiliates, and may be obligated to show acquisitions to such companies before we may pursue such acquisitions. If any of the above executive officers, directors or director nominees becomes aware of a business combination opportunity which is suitable for any of the above entities to which he or she has current fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such entity (unless presented to them in their capacity as an officer or director of our company) and only present it to us if such entity rejects the opportunity. Our sponsor, officers or directors or their respective affiliates may sponsor or form other special purpose acquisition companies similar to ours or may pursue other business or investment ventures during the period in which we are seeking an initial business combination. As a result, our sponsor (including its members), officers and directors or their respective affiliates could have conflicts of interest in determining whether to present business combination opportunities to us or to any other special purpose acquisition company with which they may become involved. Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination target, which could materially affect our ability to complete our initial business combination. Potential investors should also be aware of the following other potential conflicts of interest: • Our officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion of our initial business combination. Each of our officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs. • Our initial shareholders purchased founder shares prior to the date of this prospectus and will purchase private placement warrants in a transaction that will close simultaneously with the closing of this offering. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares and public shares in connection with the completion of our initial business combination. Additionally, our sponsor, officers and directors have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our initial business combination within the prescribed time frame, although they will be entitled to liquidating distributions from assets outside the trust account. If we do not complete our initial business combination within the prescribed time frame, the private placement warrants will expire worthless. Furthermore, our sponsor, officers and directors have agreed not to transfer, assign or sell any of their founder shares and any Class A ordinary shares issuable upon conversion thereof until the earlier to occur of: (i) one year after the completion of our initial business combination or (ii) the date following the completion of our initial business combination on which we complete a liquidation, merger, share exchange or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. Notwithstanding the foregoing, if the closing price of our Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, the founder shares will be released from the lockup. The private placement warrants (including the Class A ordinary shares issuable upon exercise of the private placement warrants) will not be transferable until 30 days following the completion of our initial business combination. Because each of our officers and director nominees will own ordinary shares or warrants directly or indirectly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. • our sponsor and members of our management team will, directly or indirectly, own our securities following this offering, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. Upon the closing of this offering, our sponsor will have invested in us an aggregate of $4,525,000, comprised of the $25,000 purchase price for the founder shares (or approximately $0.0035 per share) and the $4,500,000 purchase price for the private placement warrants (or $2.00 per warrant). Accordingly, our management team, which owns interests in our sponsor, may be more willing to pursue a business combination with a riskier or less-established target business than would be the case if our sponsor had paid the same per share price for the founder shares as our public shareholders paid for their public shares in this offering or if our sponsor were required to pay cash to exercise the private placement warrants. • certain members of our management team may receive compensation upon consummation of our initial business combination, and accordingly, they may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination as such compensation will not be received unless we consummate such business combination. • Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. • In the event our sponsor or members of our management team provide loans to us to finance transaction costs and/or incur expenses on our behalf in connection with an initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination as such loans may not be repaid and/or such expenses may not be reimbursed unless we consummate such business combination. • Similarly, if we agree to pay our sponsor, officers, directors, advisors or promoters a finder’s fee, advisory fee, consulting fee or success fee in order to effectuate the completion of our initial business combination, such persons may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination as any such fee may not be paid unless we consummate such business combination. • We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor (including its members), officers or directors or their respective affiliates, or completing the business combination through a joint venture or other form of shared ownership with our sponsor (including its members), officers or directors or their respective affiliates; accordingly, such affiliated person(s) may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination as such affiliated person(s) would have interests different from our public shareholders and would likely not receive any financial benefit unless we consummated such business combination. In the event we seek to complete our initial business combination with a company that is affiliated (as defined in our amended and restated memorandum and articles of association) with our sponsor (including its members), officers or directors or their respective affiliates, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions, stating that the consideration to be paid by us in such an initial business combination is fair to our company from a financial point of view. We are not required to obtain such an opinion in any other context. Prior to or in connection with the completion of our initial business combination, there may be payment by the company to our sponsor, officers, directors, advisors or promoters a finder’s fee, advisory fee, consulting fee or success fee in order to effectuate the completion of our initial business combination, which, if made prior to the completion of our initial business combination, will be paid from funds held outside the trust account. We cannot assure you that any of the above-mentioned conflicts will be resolved in our favor. In the event that we submit our initial business combination to our public shareholders for a vote, our sponsor, officers and directors have agreed to vote their founder shares, and they and the other members of our management team have agreed to vote their founder shares and any shares purchased during or after the offering in favor of our initial business combination, aside from shares they may purchase in compliance with the requirements of Rule 14e-5 under the Exchange Act, which would not be voted in favor of approving the business combination transaction. combination, or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees as described in the section of this prospectus entitled “Principal Shareholders — Restrictions on Transfers of Founder Shares and Private Placement Warrants”). The private placement warrants and the warrants that may be issued upon conversion of working capital loans (including the Class A ordinary shares issuable upon conversion or exercise of such warrants) will not be transferable, assignable or saleable by our sponsor (as applicable) or their permitted transferees until 30 days after the completion of our initial business combination (except with respect to permitted transferees as described herein under the section of this prospectus entitled “Principal Shareholders — Restrictions on Transfers of Founder Shares and Private Placement Warrants”).
SPAC Offering Forepart, Sponsor Compensation Material Dilution [Flag] | true
SPAC Offering Forepart, Adjusted Net Tangible Book Value Per Share [Table Text Block] |
As of June 30, 2025
Offering Price of $10.00 per Unit |  | 25% of Maximum Redemption |  | 50% of Maximum Redemption |  | 75% of Maximum Redemption |  | Maximum Redemption
NTBV |  | NTBV |  | Difference between NTBV and Offering Price |  | NTBV |  | Difference between NTBV and Offering Price |  | NTBV |  | Difference between NTBV and Offering Price |  | NTBV |  | Difference between NTBV and Offering Price
| Assuming Full Exercise of Over-Allotment Option
$ | 7.69 |  | $ | 7.12 |  | $ | 2.88 |  | $ | 6.16 |  | $ | 3.84 |  | $ | 4.24 |  | $ | 5.76 |  | (1.53 | ) |  | $ | 11.53
| Assuming No Exercise of Over-Allotment Option
$ | 7.71 |  | $ | 7.14 |  | $ | 2.86 |  | $ | 6.18 |  | $ | 3.82 |  | $ | 4.28 |  | $ | 5.72 |  | (1.45 | ) |  | $ | 11.45
SPAC Offering Forepart, Actual or Material Conflict of Interest [Flag] | true
SPAC Offering Forepart, Sponsor Compensation [Table Text Block] | The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates:
Entity/Individual |  | Amount of Compensation to be Received or Securities Issued or to be Issued |  | Consideration Paid or to be Paid
FutureCrest Acquisition Sponsor LLC |  | 7,187,500 Class B Ordinary Shares (of which 937,500 are subject to forfeiture to the extent the underwriters do not exercise their over-allotment option) |  | $25,000 or approximately $0.0035 per share
|  | 2,250,000 private placement warrants to be purchased simultaneously with the closing of this offering which warrants may be exercised on a cashless basis along with the public warrants under the circumstances specified in the warrant agreement, that may result in material dilution to our public shareholders |  | $4,500,000
|  | Up to $300,000 |  | Repayment of loans made to us to cover offering related and organizational expenses.
|  | Up to $1,500,000 in working capital loans, which loans may be convertible into warrants of the post-business combination entity at a price of $2.00 per warrant, which warrants may be exercised on a cashless basis along with the public warrants under the circumstances specified in the warrant agreement that may result in material dilution to our public shareholders |  | Working capital loans to finance transaction costs in connection with an initial business combination
|  | Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination |  | Services in connection with identifying, investigating and completing an initial business combination
Entity/Individual |  | Amount of Compensation to be Received or Securities Issued or to be Issued |  | Consideration Paid or to be Paid
Holders of Class B ordinary shares |  | Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one ratio |  | Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one basis upon conversion
Directors |  | 125,000 total founder shares for their services provided through indirect membership interests in our sponsor |  | Approximately $0.0035 per share
FutureCrest Acquisition Sponsor LLC, our officers, directors, advisors or promoters, or our or their respective affiliates |  | Finder’s fees, advisory fees, consulting fees or success fees |  | Any services in order to effectuate the completion of our initial business, which, if made prior to the completion of our initial business combination, will be paid from funds held outside the trust account
|  |  |  | We may engage our sponsor or an affiliate of our sponsor as an advisor or otherwise in connection with our initial business combination and certain other transactions and pay such person or entity a salary or fee in an amount that constitutes a market standard for comparable transactions
SPAC Prospectus Summary, Sponsor Compensation [Table Text Block] | The following table sets forth the payments to be received by our sponsor and its affiliates from us prior to or in connection with the completion of our initial business combination and the securities issued and to be issued by us to our sponsor or its affiliates:
Entity/Individual |  | Amount of Compensation to be Received or Securities Issued or to be Issued |  | Consideration Paid or to be Paid
FutureCrest Acquisition Sponsor LLC |  | 7,187,500 Class B Ordinary Shares (of which 937,500 are subject to forfeiture to the extent the underwriters do not exercise their over-allotment option) |  | $25,000 or approximately $0.0035 per share
|  | 2,250,000 private placement warrants to be purchased simultaneously with the closing of this offering, which warrants may be exercised on a cashless basis along with the public warrants under the circumstances specified in the warrant agreement that may result in material dilution to our public shareholders |  | $4,500,000
|  | Up to $300,000 |  | Repayment of loans made to us to cover offering related and organizational expenses.
|  | Up to $1,500,000 in working capital loans, which loans may be convertible into warrants of the post-business combination entity at a price of $2.00 per warrant, which warrants may be exercised on a cashless basis along with the public warrants under the circumstances specified in the warrant agreement that may result in material dilution to our public shareholders |  | Working capital loans to finance transaction costs in connection with an initial business combination
|  | Reimbursement for any out-of-pocket expenses related to identifying, investigating and completing an initial business combination |  | Services in connection with identifying, investigating and completing an initial business combination
Holders of Class B ordinary shares |  | Anti-dilution protection upon conversion into Class A ordinary shares at a greater than one-to-one ratio |  | Issuance of the Class A ordinary shares issuable in connection with the conversion of the founder shares on a greater than one-to-one basis upon conversion
Directors |  | 125,000 total founder shares for their services provided through indirect membership interests in our sponsor |  | Approximately $0.0035 per share
FutureCrest Acquisition Sponsor LLC, our officers, directors, advisors and promoters, or our or their respective affiliates |  | Finder’s fees, advisory fees, consulting fees or success fees |  | Any services in order to effectuate the completion of our initial business, which, if made prior to the completion of our initial business combination, will be paid from funds held outside the trust account We may engage our sponsor or an affiliate of our sponsor as an advisor or otherwise in connection with our initial business combination and certain other transactions and pay such person or entity a salary or fee in an amount that constitutes a market standard for comparable transactions
SPAC, Adjusted Net Tangible Book Value Per Share with Sources of Dilution [Table Text Block] | For each of the redemption scenarios above, the NTBV was calculated as follows:
|  | No Redemptions |  | 25% of Maximum Redemptions |  | 50% of Maximum Redemptions |  | 75% of Maximum Redemptions |  | Maximum Redemptions
|  | Without Over- Allotment |  | With Over- Allotment |  | Without Over- Allotment |  | With Over- Allotment |  | Without Over- Allotment |  | With Over- Allotment |  | Without Over- Allotment |  | With Over- Allotment |  | Without Over- Allotment |  | With Over- Allotment
Public offering price |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |  |  | $ | 10.00 |
Net tangible book deficit before this offering |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | ) |  |  | (0.01 | )
Increase attributable to public shareholders |  |  | 7.72 |  |  |  | 7.70 |  |  |  | 7.15 |  |  |  | 7.13 |  |  |  | 6.19 |  |  |  | 6.17 |  |  |  | 4.29 |  |  |  | 4.25 |  |  |  | (1.44 | ) |  |  | (1.52 | )
Pro forma net tangible book value after this offering and the sale of the private placement warrants |  |  | 7.71 |  |  |  | 7.69 |  |  |  | 7.14 |  |  |  | 7.12 |  |  |  | 6.18 |  |  |  | 6.16 |  |  |  | 4.28 |  |  |  | 4.24 |  |  |  | (1.45 | ) |  |  | (1.53 | )
Dilution to public shareholders |  |  | 2.29 |  |  |  | 2.31 |  |  |  | 2.86 |  |  |  | 2.88 |  |  |  | 3.82 |  |  |  | 3.84 |  |  |  | 5.72 |  |  |  | 5.76 |  |  |  | 11.45 |  |  |  | 11.53 |
Percentage of dilution to public shareholders |  |  | 22.90 | % |  |  | 23.10 | % |  |  | 28.60 | % |  |  | 28.80 | % |  |  | 38.20 | % |  |  | 38.40 | % |  |  | 57.20 | % |  |  | 57.60 | % |  |  | 114.50 | % |  |  | 115.30 | %
Numerator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net tangible book deficit before this offering |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | ) |  | $ | (38,241 | )
Net proceeds from this offering and the sale of the private placement warrants(1) |  |  | 251,250,000 |  |  |  | 288,750,000 |  |  |  | 251,250,000 |  |  |  | 288,750,000 |  |  |  | 251,250,000 |  |  |  | 288,750,000 |  |  |  | 251,250,000 |  |  |  | 288,750,000 |  |  |  | 251,250,000 |  |  |  | 288,750,000 |
Plus: Offering costs accrued for or paid in advance, excluded from tangible book value |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |  |  |  | 46,100 |
Less: Deferred underwriting commissions(2) |  |  | (10,000,000 | ) |  |  | (12,250,000 | ) |  |  | (10,000,000 | ) |  |  | (12,250,000 | ) |  |  | (10,000,000 | ) |  |  | (12,250,000 | ) |  |  | (10,000,000 | ) |  |  | (12,250,000 | ) |  |  | (10,000,000 | ) |  |  | (12,250,000 | )
Less: Over-allotment liability |  |  | (318,500 | ) |  |  | — |  |  |  | (318,500 | ) |  |  | — |  |  |  | (318,500 | ) |  |  | — |  |  |  | (318,500 | ) |  |  | — |  |  |  | (318,500 | ) |  |  | — |
Less: Amounts paid for redemptions(3) |  |  | — |  |  |  | — |  |  |  | (62,500,000 | ) |  |  | (71,875,000 | ) |  |  | (125,000,000 | ) |  |  | (143,750,000 | ) |  |  | (187,500,000 | ) |  |  | (215,625,000 | ) |  |  | (250,000,000 | ) |  |  | (287,500,000 | )
|  | $ | 240,939,359 |  |  |  | 276,507,859 |  |  |  | 178,439,359 |  |  |  | 204,632,859 |  |  |  | 115,939,359 |  |  |  | 132,757,859 |  |  |  | 53,439,359 |  |  |  | 60,882,859 |  |  |  | (9,060,641 | ) |  |  | (10,992,141 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ordinary shares outstanding prior to this offering |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |  |  |  | 7,187,500 |
Ordinary shares forfeited if over-allotment is not exercised |  |  | (937,500 | ) |  |  | — |  |  |  | (937,500 | ) |  |  | — |  |  |  | (937,500 | ) |  |  | — |  |  |  | (937,500 | ) |  |  | — |  |  |  | (937,500 | ) |  |  | — |
Ordinary shares offered and sale of private placement warrants |  |  | 25,000,000 |  |  |  | 28,750,000 |  |  |  | 25,000,000 |  |  |  | 28,750,000 |  |  |  | 25,000,000 |  |  |  | 28,750,000 |  |  |  | 25,000,000 |  |  |  | 28,750,000 |  |  |  | 25,000,000 |  |  |  | 28,750,000 |
Less: Ordinary shares redeemed |  |  | — |  |  |  | — |  |  |  | (6,250,000 | ) |  |  | (7,187,500 | ) |  |  | (12,500,000 | ) |  |  | (14,375,000 | ) |  |  | (18,750,000 | ) |  |  | (21,562,500 | ) |  |  | (25,000,000 | ) |  |  | (28,750,000 | )
|  |  | 31,250,000 |  |  |  | 35,937,500 |  |  |  | 25,000,000 |  |  |  | 28,750,000 |  |  |  | 18,750,000 |  |  |  | 21,562,500 |  |  |  | 12,500,000 |  |  |  | 14,375,000 |  |  |  | 6,250,000 |  |  |  | 7,187,500 |
____________ (1) Expenses applied against gross proceeds include offering expenses of approximately $750,000 and underwriting commissions of $0.20 per unit (including any units sold pursuant to the underwriters’ option to purchase additional units), or $5,000,000 in the aggregate, payable to Cantor Fitzgerald & Co (excluding deferred underwriting commissions). See “Use of Proceeds.” (2) Upon the consummation of our initial business combination, the deferred underwriting commissions would be paid as follows: $0.40 per unit on units other than those sold pursuant to the underwriters’ option to purchase additional units and $0.60 per unit on units sold pursuant to the underwriters’ option to purchase additional units, or $10,000,000 in the aggregate or up to $12,250,000 in the aggregate if the underwriters’ over-allotment option is exercised in full payable to Cantor Fitzgerald & Co, for deferred underwriting commissions. See also “Underwriting” for a description of compensation and other items of value payable to the underwriters. (3) If we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, our sponsor, initial shareholders, directors, officers or their respective affiliates may purchase shares or public warrants in privately negotiated transactions or in the open market either prior to or following the completion of our initial business combination. In the event of any such purchases of our shares prior to the completion of our initial business combination, the number of ordinary shares subject to redemption will be reduced by the amount of any such purchases, increasing the pro forma net tangible book value per share. See “Proposed Business — Effecting Our Initial Business Combination — Permitted Purchases of Our Securities.”

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframeDuration
Namespace Prefix: | spac_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframeExtensionFailureConsequencesToSponsorTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframeExtensionSecurityHoldersVotingOrRedemptionRightsFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframeHowExtendedTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframeLimitationsOnExtensionsTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 4 + Details
Name: | spac_DeSpacConsummationTimeframePlansIfItFailsTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 7 + Details
Name: | spac_SpacActualOrPotentialMaterialConflictOfInterestProspectusSummaryTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 5 + Details
Name: | spac_SpacAdditionalFinancingPlansImpactOnSecurityHoldersTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection c + Details
Name: | spac_SpacAdjustedNetTangibleBookValuePerShareWithSourcesOfDilutionTableTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 5 + Details
Name: | spac_SpacOfferingForepartActualOrMaterialConflictOfInterestFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 4 + Details
Name: | spac_SpacOfferingForepartAdjustedNetTangibleBookValuePerShareTableTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 1 + Details
Name: | spac_SpacOfferingForepartDeSpacConsummationTimeframe
Namespace Prefix: | spac_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 1 + Details
Name: | spac_SpacOfferingForepartDeSpacConsummationTimeframeDescriptionTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 1 + Details
Name: | spac_SpacOfferingForepartDeSpacConsummationTimeframeMayBeExtendedFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 2 + Details
Name: | spac_SpacOfferingForepartSecurityHolderRedemptionsSubjectToLimitationsFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 2 + Details
Name: | spac_SpacOfferingForepartSecurityHoldersHaveTheOpportunityToRedeemSecuritiesFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 3 + Details
Name: | spac_SpacOfferingForepartSponsorCompensationMaterialDilutionFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection a -Paragraph 3 + Details
Name: | spac_SpacOfferingForepartSponsorCompensationTableTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b + Details
Name: | spac_SpacOfferingProspectusSummaryLineItems
Namespace Prefix: | spac_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 6 + Details
Name: | spac_SpacProspectusSummarySponsorCompensationTableTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 3 + Details
Name: | spac_SpacSecuritiesOfferedRedemptionRightsTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 2 + Details
Name: | spac_SpacTrustOrEscrowAccountGrossOfferingProceedsPlacedPercent
Namespace Prefix: | spac_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 2 + Details
Name: | spac_SpacTrustOrEscrowAccountMaterialTermsTextBlock
Namespace Prefix: | spac_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 1602 -Subsection b -Paragraph 1 + Details
Name: | spac_SpacWillSolicitShareholderApprovalForDeSpacTransactionFlag
Namespace Prefix: | spac_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration